BioCentury | Oct 11, 2018
Financial News

Ophthalmology company Novaliq raises $53M

...has raised $115 million to date. The company's lead assets are CyclASol and NOV03 (Mysol). CyclASol...
...at the Ophthalmology Innovation Summit in Chicago on Oct. 25. Novaliq GmbH, Heidelberg, Germany Jaime De Leon CyclASol Mysol...
BioCentury | May 16, 2016
Clinical News

CyclASol: Completed Phase II enrollment

...topical CyclASol vs. open-label Restasis cyclosporine ophthalmic emulsion 0.05%. Novaliq GmbH , Heidelberg, Germany Product: CyclASol...
BioCentury | Feb 22, 2016
Clinical News

CyclASol: Phase II started

...a double-blind, placebo-controlled, U.S. Phase II trial to compare 2 dose levels of twice-daily topical CyclASol...
...Restasis cyclosporine ophthalmic emulsion 0.05% in about 200 patients. Novaliq GmbH , Heidelberg, Germany Product: CyclASol...
BioCentury | Oct 20, 2014
Clinical News

CyclASol: Phase I data

...crossover, dose-escalation Phase I in 18 healthy volunteers showed that single and multiple doses of CyclASol...
...clinical development of CyclASol, but did not disclose details. Novaliq GmbH , Heidelberg, Germany Product: CyclASol...
BioCentury | Apr 14, 2014
Clinical News

CyclASol: Phase I started

...evaluate multiple doses of CyclASol in 18 healthy volunteers. Novaliq GmbH , Heidelberg, Germany Product: CyclASol...
BioCentury | Apr 11, 2013
Financial News

Novaliq raises EUR 13.9 million

...only marketed product is I-Let Protect for organ preservation. Novaliq's lead compound in development is CyclASol...
Items per page:
1 - 6 of 6